参考来源:‘GSK announces US FDA approval of Benlysta (belimumab) for pediatric patients with active lupus nephritis’,新闻发布。GSK plc;2022年7月27日发布。 注:以上资讯来源于网络,由香港济民药业整理编辑(如有错漏,请帮忙指正),只为提供全球最新上市药品的资讯,帮助中国患者了解国际新药动态,仅供医护人员内...
与Benlysta相关的最常见不良反应包括恶心、腹泻、发热、鼻咽炎、支气管炎、失眠、四肢疼痛、抑郁、偏头痛和咽炎。 参考来源:‘GSK announces US FDA approval of Benlysta (belimumab) for pediatric patients with active lupus nephritis’,新闻发布。GSK plc;2022年7月27日发布。 注:以上资讯来源于网络,由香港济民...
Belimumab: Where Are We Three Years After FDA Approval?LupusBelimumabB cell therapiesBelimumab, a B cell modulator that inhibits soluble BlyS, was the first agent approved by the FDA for systemic lupus erythematosus (SLE) in over 50years. Although its licensed indication is broad, only 5% of ...
与Benlysta相关的最常见不良反应包括恶心、腹泻、发热、鼻咽炎、支气管炎、失眠、四肢疼痛、抑郁、偏头痛和咽炎。 参考来源:'GSK announces US FDA approval of Benlysta (belimumab) for pediatric patients with active lupus nephritis’,新闻发布。GSK plc;2022年7月27日发布。 注:以上资讯来源于网络,由香港济民药...
With this approval, a child's health care provider can determine if at-home administration is appropriate, and if so, the patient's caregiver can administer the medicine at home via an autoinjector once per week for children who weigh ≥40 kg or once every two weeks for children who weigh...
“We are delighted with today’s decision. Lupus can impact the lives of patients in many different ways with varied and often unpredictable symptoms. Since it launched in its IV form, thousands of patients worldwide have received treatment wit...
Management of active lupus nephritis in adults and pediatric patients ≥5 years of age.Use in conjunction with other standard therapies for lupus nephritis.The Kidney Disease-Improving Global Outcomes (KDIGO) guideline provides recommendations for treatment of lupus nephritis; belimumab may be a ...
Belimumab is a B-lymphocyte stimulator (BLyS)-specific inhibitor used to treat systemic lupus erythematosus and active lupus nephritis as an add-on therapy. Brand Names Benlysta Generic Name Belimumab DrugBank Accession Number DB08879 Background Belimumab is a fully human recombinant IgG1λ monoclonal...
Lupus Nephritis A patient with lupus nephritis may transition from intravenous therapy with BENLYSTA to subcutaneous therapy after the patient completes the first 2 intravenous doses. If transitioning, administer the first subcutaneous dose of 200 mg 1 to 2 weeks after the last intravenous dose. ...
"An effective treatment developed specifically for lupus nephritis has been desperately needed," commented Lupus Research Alliance President and CEOKenneth M. Farber. "We are particularly proud to see this approval for another indication of belimumab, having funded ...